阿昔洛韦咀嚼片致急性重度肝损伤1例分析

doi:10.19803/j.1672-8629.20250867

中国药物警戒 ›› 2026, Vol. 23 ›› Issue (9): 1056-1058.
DOI: 10.19803/j.1672-8629.20250867

阿昔洛韦咀嚼片致急性重度肝损伤1例分析

孙玲玲¹, 方薇¹, 王雨廷¹, 李进峰¹, 杨依磊^2,*

¹山东大学附属威海市立医院药剂科,山东威海 264200;
²山东第一医科大学第一附属医院（山东省千佛山医院）临床药学科,山东济南 250014

收稿日期:2025-12-01 出版日期:2026-09-15 发布日期:2026-09-15
通讯作者: ^*杨依磊,男,博士,副主任药师,临床药学。E-mail: yileiyang@126.com
作者简介:孙玲玲,女,硕士,主管药师,临床药学。
基金资助:
山东省药学会医疗机构药物警戒中青年学术课题（SDSYXH-43-2024-04）

One case of acute severe liver injury caused by chewable tablets of acyclovir

Sun Lingling¹, Fang Wei¹, Wang Yuting¹, Li Jinfeng¹, Yang Yilei^2,*

¹Department of Pharmacy, Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, Weihai Shandong 264200, China;
²Department of Clinical Pharmacy, the First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan Shandong 250014, China

Received:2025-12-01 Online:2026-09-15 Published:2026-09-15

摘要/Abstract

摘要： 目的探索阿昔洛韦咀嚼片致急性重度肝损伤病例,为临床合理用药提供参考。方法分析1例成人患者服用阿昔洛韦咀嚼片导致急性重度肝损伤的案例,评价肝损伤与阿昔洛韦咀嚼片的相关性,通过文献回顾讨论阿昔洛韦致药物性肝损伤可能机制。结果阿昔洛韦咀嚼片为患者入院前单独用药,入院后根据患者的临床表现、实验室检查及用药时间关联性评定,患者发生急性重度肝损伤很可能为阿昔洛韦咀嚼片所致,停用阿昔洛韦咀嚼片,并给予保肝治疗后,患者肝功能明显好转。结论阿昔洛韦引起肝损伤的机制尚不明确,需进一步研究证实。临床应用阿昔洛韦应警惕发生药物性肝损伤的风险,加强其不良反应监护,保障患者用药安全。

关键词: 阿昔洛韦, 咀嚼片, 肝损伤, 黄疸, 药品不良反应

Abstract: Objective To analyze a case of acute severe liver injury caused by acyclovir (ACV) chewable tablets in order to provide a reference for rational clinical use of this drug. Methods One case of acute severe liver injury induced by ACV chewable tablets in an adult patient was analyzed before the causality between acyclovir exposure and liver injury was assessed based on the clinical course, laboratory findings and temporal association with drug administration. The potential mechanism of drug-induced liver injury related to acyclovir was explored via literature review. Results Prior to hospitalization, the patient was treated with ACV chewable tablets alone. Based on clinical manifestations, laboratory tests, and the temporal correlations with medication, it was determined that the acute severe liver injury in this patient was likely caused by acyclovir chewable tablets. After acyclovir chewable tablets were discontinued and liver-protecting therapy was initiated, the liver function of this patient improved significantly. Conclusion The underlying mechanism of acyclovir-induced hepatotoxicity remains elusive. When acyclovir is used clinically, the risk of drug-induced liver injury needs to be taken into consideration while adverse reactions should be monitored to make medication safer.

Key words: Acyclovir, Chewable Tablets, Liver Injury, Icterus, Adverse Drug Reaction

中图分类号:

R978
R994.11

孙玲玲, 方薇, 王雨廷, 李进峰, 杨依磊. 阿昔洛韦咀嚼片致急性重度肝损伤1例分析[J]. 中国药物警戒, 2026, 23(9): 1056-1058.

Sun Lingling, Fang Wei, Wang Yuting, Li Jinfeng, Yang Yilei. One case of acute severe liver injury caused by chewable tablets of acyclovir[J]. Chinese Journal of Pharmacovigilance, 2026, 23(9): 1056-1058.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://zgywjj.magtechjournal.com/CN/10.19803/j.1672-8629.20250867

https://zgywjj.magtechjournal.com/CN/Y2026/V23/I9/1056

参考文献

[1] Franzin M, Ruoso R, Del Savio R, et al.Development and validation of an HPLC-UV method for the quantification of acyclovir and ganciclovir in the plasma of pediatric immunocompromised patients[J]. Int J Mol Sci, 2024, 25(5): 2685.
[2] Karloff D B, Stubbs R T, Ibukun O J, et al.Glyoxal caging of nucleoside antivirals toward self-activating, extended-release prodrugs[J]. J Am Chem Soc, 2024, 146(43): 29402-29406.
[3] Matsuoka S, Petri G, Larson K, et al.Evaluation of histone demethylase inhibitor ML324 and acyclovir against cyprinid herpesvirus 3 infection[J]. Viruses, 2023, 15(1): 163.
[4] Shen S J, Feng P C, Wu R C, et al.Resorbable nanofibrous membranes for local and sustained co-delivery of acyclovir and ketorolac in herpes therapy[J]. Int J Pharm, 2024, 654: 123988.
[5] Sile B, Brown K E, Gower C, et al.Effectiveness of oral acyclovir in preventing maternal chickenpox: a comparison with VZIG[J]. J Infect, 2022, 85(2): 147-151.
[6] He D, Kong D X, Zeng Y B, et al.Differences in safety profiles of anti-herpesvirus medications: a real-world pharmacovigilance study based on the FAERS database[J]. Expert Opin Drug Saf, 2025, 24(12): 1487-1496.
[7] Liu Jikai, Zhang Fufang.One case of abnormal liver function caused by acyclovir[J]. Clinical Focus(临床荟萃), 2000, 15(4): 184.
[8] Zhang Wen, Jiang Li, Zhou Haofeng, et al.Pharmaceutical care for a child with drug-induced liver injury induced by acyclovir[J]. China Pharmaceuticals(中国药业), 2022, 31(6): 114-117.
[9] Joseph J, Green W, Lippert J, et al.S2793 Drug-induced liver injury secondary to intravenous acyclovir: a rare side effect[J]. The American Journal of Gastroenterology, 2021, 116(10 Suppl): 1.
[10] Li Yin, Gu Zhengxiang, Hu Jiaxin, et al.A case report of suspected drug-induced liver injury caused by acyclovir in children[J]. Journal of Women and Children's Health Guide(妇儿健康导刊), 2024, 3(7): 94-97.
[11] Study Group of Drug Induced Liver Disease of Chinese Medical Association. Diagnosis and treatment guideline on drug-induced liver injury[J]. Chinese Journal of Hepatology(中华肝脏病杂志), 2015, 23(11): 810-820.
[12] Zhang Yanan, Yang Hongxin, Zhang Li, et al.Comparative evaluation of the correlation between Naranjo's assessment scale and the judgment criteria of the national center for adverse drug reaction monitoring on the association of drospirenone and ethinylestradiol tablets with pulmonary embolism[J]. Journal of Disease Monitor and Control(疾病监测与控制), 2023, 17(6): 430-434.
[13] Technology Committee on DILI Prevention and Management, Chinese Medical Biotechnology Association, Study Group of Drug-Induced Liver Disease, Chinese Medical Association for the Study of Liver Diseases. Chinese guideline for diagnosis and management of drug-induced liver injury (2023 version)[J]. Chin J Hepatol(中华肝脏病杂志), 2023, 31(4): 355-384.
[14] Izzedine H, Launay-Vacher V, Deray G.Antiviral drug-induced nephrotoxicity[J]. Am J Kidney Dis, 2005, 45(5): 804-817.
[15] Jia Zhenrong.Study on the toxicity of three anti-virus drugs of nucleosides to primary hepatocytes of rats[D]. Wuhan: Huazhong Agricultural University, 2006.
[16] Hoofnagle J H, Bjornsson E S.Drug-induced liver injury-types and phenotypes[J]. N Engl J Med, 2019, 381(3): 264-273.

阿昔洛韦咀嚼片致急性重度肝损伤1例分析

One case of acute severe liver injury caused by chewable tablets of acyclovir

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	冯思琪, 倪雨晨, 胡冯译, 刘玥, 叶小飞, 郭晓晶. 细胞治疗产品上市后长期安全性监测的国际经验与中国优化路径[J]. 中国药物警戒, 2026, 23(9): 975-981.
[2]	刘红亮, 宋海波, 米岚, 孟康康, 王涛, 漆燕, 贾晋生. 基于大语言模型应用的个例安全性报告数据清洗方法探讨[J]. 中国药物警戒, 2026, 23(9): 1017-1022.
[3]	赵志伟, 柯文缘, 杨雪, 陈晓博, 夏旭东. 1358例碘克沙醇注射液不良反应报告分析[J]. 中国药物警戒, 2026, 23(9): 1040-1044.
[4]	潘恩, 崔小康, 徐滨, 荣右明, 范晓, 马晓东, 李霞. 1115例草酸艾司西酞普兰片不良反应报告分析[J]. 中国药物警戒, 2026, 23(9): 1045-1049.
[5]	尚家海, 龙娇娇, 刘雅瑞, 卢圆圆. 注射用尖吻蝮蛇血凝酶致儿童结膜充血2例分析[J]. 中国药物警戒, 2026, 23(9): 1050-1052.
[6]	吴倩, 覃勇, 望庐山, 韩忠宇. 吉非替尼片致心肌炎1例分析[J]. 中国药物警戒, 2026, 23(9): 1053-1055.
[7]	王昆, 徐磊, 汪岑, 侯文平, 刘俊保, 苏长海. 地高辛片致舞蹈症1例分析[J]. 中国药物警戒, 2026, 23(9): 1059-1061.
[8]	邢璐宇, 邢迎红, 范文, 张淑翼. 注射用哌拉西林钠他唑巴坦钠致横纹肌溶解1例分析[J]. 中国药物警戒, 2026, 23(9): 1062-1064.
[9]	向群, 傅大莉. 药源性认知障碍的致病药物及疾病风险评估研究进展[J]. 中国药物警戒, 2026, 23(9): 1075-1080.
[10]	吕欣鸽, 刘艾嘉, 武一, 潘晨, 王雨婷, 崔向丽. 免疫检查点抑制剂相关甲状腺功能障碍的多中心病例分析[J]. 中国药物警戒, 2026, 23(8): 892-897.
[11]	李剑屏, 杜宁, 唐敏, 周子原, 左靖. 691例新型抗肿瘤药品不良反应报告分析[J]. 中国药物警戒, 2026, 23(8): 904-908.
[12]	白丽琴, 聂红科, 杨淑婷, 蒋晓峰. 214例肌苷注射液不良反应报告分析[J]. 中国药物警戒, 2026, 23(8): 909-913.
[13]	张育茂, 刘君波, 罗千江, 谭槟滢, 邓彬, 邢惟青, 李玉珍. 口服复方聚乙二醇电解质散（Ⅱ）肠道准备致呕血2例分析[J]. 中国药物警戒, 2026, 23(8): 931-933.
[14]	高朝政, 赵一帆, 苏丽, 李平. 注射用芦康沙妥珠单抗致癌症患者急性疼痛2例分析[J]. 中国药物警戒, 2026, 23(8): 934-937.
[15]	谢华丽, 关碧茜, 卓羽波, 何洁丽, 陈喆. 注射用芦康沙妥珠单抗致序贯性超敏反应1例分析[J]. 中国药物警戒, 2026, 23(8): 938-940.